<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>DYT locus symbols for dystonia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">DYT locus symbols for dystonia</h1>
<div class="graphic"><div class="figure"><div class="ttl">DYT locus symbols for dystonia</div><div class="cntnt"><table cellspacing="0"><colgroup span="5" width="20%"></colgroup> <tbody> <tr> <td class="subtitle1">Locus</td> <td class="subtitle1">Designation</td> <td class="subtitle1">Mode of inheritance</td> <td class="subtitle1">Clinical features</td> <td class="subtitle1">Chromosome, mutation, and gene product</td> </tr> <tr> <td>DYT1</td> <td>Dystonia 1, torsion</td> <td>AD</td> <td>Typically begins in childhood; onset in limb often with progression to generalized dystonia</td> <td>9q34; GAG deletion in <em>TOR1A</em> gene causes abnormality in ATP-binding protein, torsinA</td> </tr> <tr class="highlight_gray_text"> <td>DYT2</td> <td>Dystonia 2, torsion</td> <td>AR</td> <td>Childhood onset, generalized or segmental; Roma families</td> <td>1p35.1; <em>HPCA</em> gene that encodes hippocalcin</td> </tr> <tr> <td>DYT3</td> <td>X-linked dystonia-parkinsonism (Lubag)</td> <td>X-linked recessive</td> <td>Segmental or generalized dystonia with parkinsonism; predominantly in males from Panay island in Philippines</td> <td>Xq13.1; <em>TAF1</em> gene</td> </tr> <tr class="highlight_gray_text"> <td>DYT4</td> <td>Whispering dysphonia</td> <td>AD</td> <td>Laryngeal and cervical dystonia, often with progression to generalized dystonia</td> <td>19p13.3; mutations in the <em>TUBB4A</em> gene</td> </tr> <tr> <td rowspan="2">DYT5</td> <td>Dopa-responsive dystonia/parkinsonism</td> <td>AD</td> <td>Dystonia with or without parkinsonism; dramatic response to levodopa</td> <td>14q22; <em>GCH1</em> locus; mutations in GTP cyclohydrolase I gene</td> </tr> <tr> <td>Segawa syndrome</td> <td>AR</td> <td>Dystonia with or without parkinsonism; diurnal variation, with worst symptoms in evening; marked response to levodopa</td> <td>11p15.5; mutations in the tyrosine hydroxylase gene; tyrosine hydroxylase deficiency</td> </tr> <tr class="highlight_gray_text"> <td>DYT6</td> <td>Dystonia 6, torsion</td> <td>AD</td> <td>Adolescent-onset dystonia of mixed type; mostly segmental dystonia; mixed limb, cervical, cranial; Amish-Mennonite, German, Irish, Italian families</td> <td>8p11.21; mutations in the <em>THAP1</em> gene</td> </tr> <tr> <td>DYT7</td> <td>Dystonia 7, torsion</td> <td>AD</td> <td>Adult-onset focal dystonia with cervical dystonia, limb dystonia, dysphonia, or blepharospasm; German family</td> <td>18p; gene and product unknown</td> </tr> <tr class="highlight_gray_text"> <td>DYT8</td> <td>Paroxysmal nonkinesigenic dyskinesia 1</td> <td>AD</td> <td>Episodes of dystonia/choreoathetosis not precipitated by exercise or activity</td> <td>2q35; <em>MR1</em> gene involved in myofibrillogenesis regulation</td> </tr> <tr> <td>DYT9 (allelic with DYT18)</td> <td>Paroxysmal choreoathetosis with episodic spasticity and ataxia</td> <td>AD</td> <td>Episodes of dystonia, diplopia, and paresthesia with spastic paraplegia between attacks</td> <td>1p34.2; mutations in the <em>SLC2A1</em> gene that encodes the glucose transporter type 1</td> </tr> <tr class="highlight_gray_text"> <td>DYT10</td> <td>Episodic kinesigenic dyskinesia 1 (paroxysmal kinesigenic dyskinesia)</td> <td>AD</td> <td>Episodic choreoathetosis and dystonia brought on by exercise/activity</td> <td>16p11.2; mutations in the <em>PRRT2</em> gene</td> </tr> <tr> <td>DYT11</td> <td>Myoclonus-dystonia</td> <td>AD</td> <td>Myoclonic jerks associated with variable features of dystonia; very alcohol responsive</td> <td>7q; epsilon-sarcoglycan gene (<em>SGCE</em>)</td> </tr> <tr class="highlight_gray_text"> <td>DYT12</td> <td>Rapid-onset dystonia-parkinsonism</td> <td>AD</td> <td>Onset of dystonia and parkinsonism over days to months</td> <td>19q; <em>ATP1A3</em> gene that encodes the Na+/K+ -ATPase alpha3 subunit</td> </tr> <tr> <td>DYT13</td> <td>Dystonia 13, torsion</td> <td>AD</td> <td>Early adult-onset multifocal and segmental dystonia with cervical, cranial, and arm dystonia</td> <td>1p36.32-p36.13; gene and product unknown</td> </tr> <tr class="highlight_gray_text"> <td>DYT14</td> <td>Dopa-responsive dystonia (now included under DYT5)</td> <td> </td> <td> </td> <td> </td> </tr> <tr> <td>DYT15</td> <td>Dystonia 15, myoclonic</td> <td>AD</td> <td>Myoclonus and dystonia</td> <td>18p11; gene and product unknown</td> </tr> <tr class="highlight_gray_text"> <td>DYT16</td> <td>Dystonia 16</td> <td>AR</td> <td>Early-onset generalized dystonia; some cases with parkinsonism unresponsive to levodopa</td> <td>2q31.3; <em>PRKRA</em> gene</td> </tr> <tr> <td>DYT17</td> <td>Dystonia 17, torsion</td> <td>AR</td> <td>Adolescent onset in neck with regional spread</td> <td>20p11.2-q13.12; gene and product unknown</td> </tr> <tr class="highlight_gray_text"> <td>DYT18 (allelic with DYT9)</td> <td>Paroxysmal exercise-induced dyskinesia with or without epilepsy and/or hemolytic anemia (GLUT1 deficiency syndrome 2)</td> <td>AD</td> <td>Episodes of dystonia, diplopia, paresthesias with spastic paraplegia between attacks</td> <td>1p34.2; mutations in the <em>SLC2A1</em> gene that encodes the glucose transporter type 1</td> </tr> <tr> <td>DYT19</td> <td>Episodic kinesigenic dyskinesia 2 (paroxysmal kinesigenic dyskinesia)</td> <td>AD</td> <td>Episodic choreoathetosis and dystonia brought on by exercise/activity</td> <td>16q13-q22.1; gene and product unknown</td> </tr> <tr class="highlight_gray_text"> <td>DYT20</td> <td>Paroxysmal nonkinesigenic dyskinesia 2</td> <td>AD</td> <td>Spontaneous episodes of dystonia</td> <td>2q31; gene and product unknown</td> </tr> <tr> <td>DYT21</td> <td>Dystonia 21</td> <td>AD</td> <td>Adolescent to adult onset; generalized or multifocal</td> <td>2q14.3-q21.3; gene and product unknown</td> </tr> <tr class="highlight_gray_text"> <td>DYT23</td> <td>Dystonia 23</td> <td>AD</td> <td>Adult-onset cervical dystonia</td> <td>9q34, <em>CIZ1</em> gene</td> </tr> <tr> <td>DYT24</td> <td>Dystonia 24</td> <td>AD</td> <td>Adult-onset craniocervical dystonia affecting the neck, laryngeal muscles, and arms</td> <td>11p14.2, <em>ANO3</em> gene</td> </tr> <tr class="highlight_gray_text"> <td>DYT25</td> <td>Dystonia 25</td> <td>AD</td> <td>Adult-onset cervical dystonia with regional spread</td> <td>18p11.21, <em>GNAL</em> gene</td> </tr> <tr> <td>DYT26</td> <td>Dystonia 26, myoclonic</td> <td>AD</td> <td>Myoclonus in the first decades of life; craniocervical dystonia develops eventually</td> <td>22p12.3; <em>KCTD17</em> gene encoding the BTB/POZ domain-containing protein KCTD17</td> </tr> <tr class="highlight_gray_text"> <td>DYT27</td> <td>Dystonia 27</td> <td>AR</td> <td>Segmental isolated craniocervical and limb dystonia in the first decades of life</td> <td>2q37.3; <em>COL6A3</em> gene encoding the collagen type VI alpha 3 chain</td> </tr> <tr> <td>DYT28</td> <td>Dystonia 28, childhood onset</td> <td>AD</td> <td>Childhood-onset caudal dystonia with rostral progression, intellectual disabilities, and dysmorphia</td> <td>19q13.12; <em>KMT2B</em> gene encoding the histone-lysine N-methyltransferase 2B protein</td> </tr> <tr class="highlight_gray_text"> <td>DYT29</td> <td>Dystonia 29, childhood onset with optic atrophy and basal ganglia abnormalities</td> <td>AR</td> <td>Onset of dystonia and optic atrophy in the first decade of life</td> <td>1p35.3; <em>MECR</em> gene</td> </tr> <tr> <td>DYT30</td> <td>Dystonia 30</td> <td>AD</td> <td>Early-onset upper body dystonia with eventual generalization</td> <td>20p13; <em>VPS16</em> gene encoding the VPS16 core subunit of CORVET and HOPS complexes</td> </tr> <tr class="highlight_gray_text"> <td>DYT31</td> <td>Dystonia 31</td> <td>AR</td> <td>Progressive generalized dystonia with orofacial dyskinesias causing dysarthria and dysphagia</td> <td>9q22.32; <em>AOPEP</em> gene encoding aminopeptidase O</td> </tr> <tr> <td>DYT32</td> <td>Dystonia 32</td> <td>AR</td> <td>Adult-onset, slowly progressive dystonia with eventual generalization complicated by dysarthria and dysphagia</td> <td>11q23.3; <em>VPS11</em> gene encoding the VPS11 core subunit of CORVET and HOPS complexes</td> </tr> <tr class="highlight_gray_text"> <td>DYT33</td> <td>Dystonia 33</td> <td>AD, AR</td> <td>Childhood- to adolescent-onset, slowly progressive focal or generalized dystonia</td> <td>2p22.2; <em>EIF2AK2</em> gene encoding the eukaryotic translation initiation factor 2-alpha kinase 2</td> </tr> <tr> <td>DYT34</td> <td>Myoclonic dystonia 34</td> <td>AD</td> <td>Childhood-onset dystonia involving the hands and neck with tremor and superimposed myoclonus</td> <td>5q22.3; <em>KCNN2</em> gene encoding potassium calcium-activated channel subfamily N member 2</td> </tr> </tbody></table></div><div class="graphic_footnotes">AD: autosomal dominant; ATP: adenosine triphosphate; AR: autosomal recessive.</div><div id="graphicVersion">Graphic 56658 Version 17.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
